MarketLine Company Profile: Novavax, Inc.

Source: Novavax, Inc. MarketLine Company Profile. 12/6/2024, p1-32. 32p.

Subject Terms: *Pharmaceutical industry

Geographic Terms: United States

Company/Entity: Novavax Inc. 808837520 NOX

Novavax, Inc. SWOT Analysis.

Source: Novavax, Inc. SWOT Analysis. 12/6/2024, p1-7. 7p.

Subject Terms: *SWOT analysis, Biopharmaceutics

Geographic Terms: Gaithersburg (Md.)

Company/Entity: Novavax Inc. 808837520 NOX

Analysis of Allergy and Hypersensitivity Reactions to COVID-19 Vaccines According to the EudraVigilance Database.

Authors: Romantowski, Jan¹ (AUTHOR) jromant@gumed.edu.pl, Nazar, Wojciech² (AUTHOR) wojciech.nazar@gumed.edu.pl, Bojahr, Kinga¹ (AUTHOR), Popiołek, Iwona³ (AUTHOR) iwona.popiolek@uj.edu.pl, Niedoszytko, Marek¹ (AUTHOR)

Source: Life (2075-1729). Jun2024, Vol. 14 Issue 6, p715. 14p.

Subject Terms: *COVID-19 vaccines, *DATABASES, *PATIENT-professional relations, *COVID-19, *MEDICAL personnel as patients

Company/Entity: EUROPEAN Economic Area , NOVAVAX Inc. 808837520 NOX

MarketLine Company Profile: Novavax, Inc.

Source: Novavax, Inc. MarketLine Company Profile. 7/21/2023, p1-31. 31p.

Subject Terms: *Pharmaceutical industry

Geographic Terms: United States

Company/Entity: Novavax Inc. 808837520 NOX

Novavax, Inc. SWOT Analysis.

Source: Novavax, Inc. SWOT Analysis. 7/21/2023, p1-7. 7p.

Subject Terms: *SWOT analysis, Biopharmaceutics

Geographic Terms: Gaithersburg (Md.)

Company/Entity: Novavax Inc. 808837520 NOX

COVID-19 vaccines in 2023.

Authors: Sharma, Ketaki¹, Li-Kim-Moy, Jean¹

Source: Australian Prescriber. Oct2023, Vol. 46 Issue 3, p60-63. 4p.

Subject Terms: *COVID-19 vaccines, *SARS-CoV-2 Omicron variant, *BOOSTER vaccines, *SARS-CoV-2, *COVID-19

Company/Entity: NOVAVAX Inc. 808837520 NOX, PFIZER Inc. 001326495 PFE

MarketLine Company Profile: Novavax, Inc.

Source: Novavax, Inc. MarketLine Company Profile. 11/2/2022, p1-28. 28p.

Subject Terms: *Pharmaceutical industry

Geographic Terms: United States

Company/Entity: Novavax Inc. 808837520 NOX

Novavax, Inc. SWOT Analysis.

Source: Novavax, Inc. SWOT Analysis. 11/2/2022, p1-7. 7p.

Subject Terms: *SWOT analysis, Biopharmaceutics

Geographic Terms: Gaithersburg (Md.)

Company/Entity: Novavax Inc. 808837520 NOX

MarketLine Company Profile: Novavax, Inc.

Source: Novavax, Inc. MarketLine Company Profile. 12/29/2021, p1-28. 28p.

Subject Terms: *Pharmaceutical industry

Geographic Terms: United States

Company/Entity: Novavax Inc. 808837520 NOX

Novavax, Inc. SWOT Analysis.

Source: Novavax, Inc. SWOT Analysis. 12/29/2021, p1-7. 7p.

Subject Terms: *SWOT analysis, Biopharmaceutics

Geographic Terms: Gaithersburg (Md.)

Company/Entity: Novavax Inc. 808837520 NOX

FDA puts Novavax's phase 3 plan for pair of vaccine programs on hold over nerve disease case.

Authors: Waldron, James (AUTHOR)

Source: FierceBiotech. 10/16/2024, pN.PAG-N.PAG. 1p.

Subject Terms: *COVID-19, Motor neuron diseases, Neurological disorders, Influenza vaccines, Vaccines

Company/Entity: Novavax Inc. 808837520 NOX

Novavax Plunges After FDA Hold on Flu, Covid Vaccine Work.

Authors: Rutherford, Fiona (AUTHOR), Suvarna, Rthvika (AUTHOR)

Source: Bloomberg.com. 10/17/2024, pN.PAG-N.PAG. 1p.

Subject Terms: *COVID-19 vaccines, *COVID-19 pandemic, *Stock prices, Combined vaccines, Motor neuron diseases

Company/Entity: Novavax Inc. 808837520 NOX, United States. Food & Drug Administration

Novavax Studies for Flu, Covid Vaccines on Hold Over Safety.

Authors: Rutherford, Fiona (AUTHOR), Suvarna, Rthvika (AUTHOR)

Source: Bloomberg.com. 10/16/2024, pN.PAG-N.PAG. 1p.

Subject Terms: *COVID-19 vaccines, *COVID-19 pandemic, *Stock prices, Combined vaccines, Motor neuron diseases

Company/Entity: Novavax Inc. 808837520 NOX

Novavax Shares Plunge After FDA Places a Hold on Its Flu Shots.

Authors: Rutherford, Fiona (AUTHOR), Suvarna, Rthvika (AUTHOR)

Source: Bloomberg.com. 10/16/2024, pN.PAG-N.PAG. 1p.

Subject Terms: *COVID-19 vaccines, *Stock prices, Motor neuron diseases, Influenza vaccines, Influenza

Company/Entity: Novavax Inc. 808837520 NOX, United States. Food & Drug Administration

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.

Authors: Bennett, Chijioke¹ (AUTHOR) cbennett@novavax.com, Woo, Wayne¹ (AUTHOR), Bloch, Mark^2,3 (AUTHOR), Cheung, King⁴ (AUTHOR), Griffin, Paul^5,6 (AUTHOR), Mohan, Rahul⁷ (AUTHOR), Deshmukh, Sachin⁸ (AUTHOR), Arya, Mark⁹ (AUTHOR), Cumming, Oscar¹⁰ (AUTHOR), Neville, A Munro¹¹ (AUTHOR), McCallum Pardey, Toni G¹⁰ (AUTHOR), Plested, Joyce S¹ (AUTHOR), Cloney-Clark, Shane¹ (AUTHOR), Zhu, Mingzhu¹ (AUTHOR), Kalkeri, Raj¹ (AUTHOR), Patel, Nita¹ (AUTHOR), Marcheschi, Alex¹ (AUTHOR), Swan, Jennifer¹ (AUTHOR), Smith, Gale¹ (AUTHOR), Cho, Iksung¹ (AUTHOR)

Source: Lancet Infectious Diseases. Jun2024, Vol. 24 Issue 6, p581-593. 13p.

Subject Terms: *BOOSTER vaccines, *SARS-CoV-2 Omicron variant, *IMMUNE response, *SARS-CoV-2, *CLINICAL trials

Geographic Terms: AUSTRALIA

Company/Entity: NOVAVAX Inc. 808837520 NOX

Benefit–risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).

Authors: Fix, Jonathan¹ (AUTHOR) Jfix@novavax.com, Christopher Mast, T.¹ (AUTHOR), Smith, Katherine¹ (AUTHOR), Baker, Nicole¹ (AUTHOR)

Source: Vaccine. Apr2024, Vol. 42 Issue 9, p2161-2165. 5p.

Subject Terms: *COVID-19 vaccines, *COVID-19, *VACCINE effectiveness, *COVID-19 pandemic, *MYOCARDITIS

Company/Entity: NOVAVAX Inc. 808837520 NOX

Chutes & Ladders—Acadia brings BMS vet on board as CEO.

Authors: Incorvaia, Darren (AUTHOR), Becker, Zoey (AUTHOR)

Source: FierceBiotech. 9/27/2024, pN.PAG-N.PAG. 1p.

Subject Terms: *Expertise, *Chief executive officers, *Leadership, Clinical trials, Drugs

Company/Entity: Novavax Inc. 808837520 NOX

Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.

Authors: Bricker, Traci L.¹, Joshi, Astha¹, Soudani, Nadia^1,2, Scheaffer, Suzanne M.¹, Patel, Nita³, Guebre-Xabier, Mimi³, Smith, Gale³, Diamond, Michael S.^1,2,4, Boon, Adrianus C. M.^1,2,4 jboon@wustl.edu

Source: Journal of Virology. Mar2024, Vol. 98 Issue 3, p1-14. 14p.

Subject Terms: *SARS-CoV-2, *SARS-CoV-2 Omicron variant, *GOLDEN hamster, *NANOPARTICLES, *IMMUNOGLOBULINS

Geographic Terms: WUHAN (China)

Company/Entity: NOVAVAX Inc. 808837520 NOX

MarketLine Company Profile: Novavax, Inc.

Source: Novavax, Inc. MarketLine Company Profile. 3/13/2020, p1-26. 26p.

Subject Terms: *Pharmaceutical industry

Geographic Terms: United States

Company/Entity: Novavax Inc. 808837520 NOX

Novavax, Inc. SWOT Analysis.

Source: Novavax, Inc. SWOT Analysis. 3/13/2020, p1-6. 6p.

Subject Terms: *SWOT analysis, Biopharmaceutics

Geographic Terms: Gaithersburg (Md.)

Company/Entity: Novavax Inc. 808837520 NOX